Overview

Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects

Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This clinical study will examine the safety and tolerability, as well as the effects of orally administered mizagliflozin on post prandial glucose and insulin levels in subjects diagnosed with post-bariatric hypoglycemia (PBH).
Phase:
Phase 2
Details
Lead Sponsor:
Vogenx, Inc.